Published on
In a study of 31,900 healthy term infants at Kaiser Permanente Northern California during the 2023–2024 respiratory syncytial virus (RSV)-season, researchers found nirsevimab demonstrated high effectiveness in preventing RSV-associated lower respiratory tract disease (LRTD), as published in Pediatrics. Among immunized infants (49.1%), the incidence of RSV-associated LRTD was 6.10 per 1,000 person-years compared to 58.51 in non-immunized infants (95% confidence interval [CI], 81.7%–91.1%; P<0.001). Effectiveness against hospitalized RSV LRTD was 98.0% (95% CI, 85.1%–99.7%). Immunized infants with RSV LRTD had significantly fewer healthcare encounters (mean difference −0.86; P=0.001) and lower odds of hospitalization (odds ratio [OR], 0.11; 95% CI, 0.01–0.85) than non-immunized infants in the study.
Relatively new preventive care: Authors say their real-world results support nirsevimab’s clinical benefit in routine outpatient use among healthy term infants. Of note, the study excluded infants who were born to mothers who received an RSV vaccine during pregnancy. Nirsevimab was approved in 2023 and is administered as a single dose, typically before or during the RSV season, which begins around October.
Read More
- New RSV Vaccine Approved For Infants
- RSV Vaccine Effective For Older Adults
- RSV Vaccine Likely Improved Last Year’s Infant Mortality Rate